Loading...
XETR
M12
Market cap398mUSD
Dec 05, Last price  
18.24EUR
1D
-5.59%
1Q
34.71%
Jan 2017
72.97%
IPO
250.77%
Name

M1 Kliniken AG

Chart & Performance

D1W1MN
XETR:M12 chart
P/E
21.38
P/S
1.01
EPS
0.85
Div Yield, %
2.74%
Shrs. gr., 5y
1.18%
Rev. gr., 5y
34.44%
Revenues
339m
+7.23%
6,081,00023,017,00034,926,33435,955,00047,194,52565,208,58677,216,857159,590,839314,610,275285,291,186316,318,613339,184,017
Net income
16m
+55.91%
109,0004,585,0006,630,7555,007,4605,777,9716,612,5679,729,0306,823,0108,905,0914,317,35410,274,28316,018,451
CFO
31m
+242.55%
-5,215,000912,575-171,7967,936,0002,085,9642,860,919-3,524,3119,381,13415,658,05521,023,1318,917,09630,545,871
Dividend
Jul 18, 20240.5 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products and devices in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, management, and sale of real estate, primarily in the health care sector. It offers its products to doctors, pharmacies, and wholesalers under the M1 Select brand. The company operates a network of outpatient specialist centers; and a specialized surgical clinic center, as well as 46 specialist centers under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.
IPO date
Sep 14, 2015
Employees
366
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT